MEDIKIT CO.,LTD (7749) Stock Price

Medikit Corporation is a company engaged in the development, manufacturing, and sales of medical devices. The company consists of Medikit Corporation and four consolidated subsidiaries, and primarily handles medical devices related to blood vessels and blood. Manufacturing is carried out by Togo Medikit Corporation and Medikit Vietnam Co., Ltd., while Medikit Corporation procures these products and sells them to users both domestically and internationally.

Medikit's business operates as a single segment, with products classified by category. First, in hemodialysis-related products, the company manufactures and sells hemodialysis catheters used during blood dialysis treatment for chronic kidney failure. The flagship product is "Happy Cath," which is used in dialysis procedures performed approximately 150 times annually. The design prioritizes reducing patient discomfort and preventing blood vessel damage.

Second, in peripheral venous catheters, the company manufactures and sells needles used for blood transfusions and intravenous infusions. These needles are used when administering intravenous fluids through peripheral veins for purposes such as nutritional supplementation. Products with needle stick injury prevention features have also been developed, with "Super Cath" as a flagship product. The design incorporates features to ensure safe use by medical staff.

Additionally, in interventional products, the company performs diagnostic and therapeutic procedures using catheter systems. The company manufactures and sells sheath introducers and catheters used in angiography and endovascular treatment. These products are primarily used for diagnostic and therapeutic procedures on lesions accessed through blood vessels in the head, abdomen, and heart. Flagship products include "Super Sheath" and "Medikit Angiographic Catheter."

Medikit Corporation aims to contribute to society through the development, manufacturing, and sales of medical devices. The company's vision is to provide safe and effective medical devices developed in Japan to healthcare professionals worldwide, guided by the keywords "trust and empathy." The company has adopted "innovation, speed, and reliability" as its operational principles, striving to deliver high-quality products and services that advance medical practice.

Medikit has established an integrated system spanning product development, production, and sales. By operating as separate entities—Medikit Corporation as the sales company and Togo Medikit Corporation handling development and manufacturing—the company clarifies each division's role and pursues a balance between growth and profitability. This structure enables the efficient delivery of high-quality products to customers.

The company has formulated a medium-term management plan titled "NEXT 300 Neo" through fiscal year 2028, targeting net sales of ¥29.0–32.0 billion, an average annual growth rate of 5.5–8.5%, and an operating profit margin of 18%. To achieve these goals, the company has identified three priority areas: development of intervention products, strengthened sales in Western and Chinese markets, and improved production efficiency. Through these initiatives, Medikit seeks to enhance growth and profitability.

Additionally, Medikit has identified five key priorities: social contribution through healthcare, creating a workplace where diverse talent can thrive, strengthening the management foundation, reducing environmental impact, and contributing to local communities. By addressing these priorities, the company aims to realize a sustainable society and enhance corporate value.